As the top communicator at the world's largest bio-pharma company, Sally Susman is always insanely busy. This year has been – and will be – no exception.
On the heels of CEO Jeffrey Kindler's resignation late last year, Susman led a restructuring of the in-house communications team with an eye on aligning the function more closely with the company's other business units. This also removed a layer of management that had existed under Kindler, thus moving Susman even closer to the new CEO Ian Read.
And the news keeps coming from Pfizer. Last month it announced the launch of the first-ever home-based clinical trial program, which will allow patients to take part in an experimental therapy program through social media. And in November, Pfizer's patent on the hugely popular cholesterol drug Lipitor expires. Susman will have a major role in shaping the messaging around both these major developments.